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Background: Comparative gene expression profiling analysis is useful in discovering differentially expressed genes
associated with various diseases, including mental disorders. Autism spectrum disorders (ASD) are a group of
complex childhood-onset neurodevelopmental and genetic disorders characterized by deficits in language
development and verbal communication, impaired reciprocal social interaction, and the presence of repetitive
behaviors or restricted interests. The study aimed to identify novel genes associated with the pathogenesis of ASD.
Methods: We conducted comparative total gene expression profiling analysis of lymphoblastoid cell lines (LCL)
between 16 male patients with ASD and 16 male control subjects to screen differentially expressed genes
associated with ASD. We verified one of the differentially expressed genes, FOXP1, using real-time quantitative PCR
(RT-qPCR) in a sample of 83 male patients and 83 male controls that included the initial 16 male patients and male
controls, respectively.
Results: A total of 252 differentially expressed probe sets representing 202 genes were detected between the two
groups, including 89 up- and 113 downregulated genes in the ASD group. RT-qPCR verified significant elevation of
the FOXP1 gene transcript of LCL in a sample of 83 male patients (10.46 ± 11.34) compared with 83 male controls
(5.17 ± 8.20, P = 0.001).
Conclusions: Comparative gene expression profiling analysis of LCL is useful in discovering novel genetic markers
associated with ASD. Elevated gene expression of FOXP1 might contribute to the pathogenesis of ASD.
Clinical trial registration: Identifier: NCT00494754
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Autism spectrum disorders (ASD) represent a constellation
of childhood-onset neurodevelopmental disorders char-
acterized by three core symptom domains: deficits in
reciprocal social interactions, impairments in language
development and verbal communication, and the presence
of stereotyped, repetitive behaviors and restricted interests
[1]. The clinical presentations of ASD are highly heteroge-
neous with varied expressivity and differences in the severity
of clinical symptoms and functional impairments. The
estimated prevalence of ASD in the general population* Correspondence: gaushufe@ntu.edu.tw; cchen3801@gmail.com
2Department of Psychiatry, National Taiwan University College of Medicine,
No.1 Jen-Ai Rd. Section 1, Taipei, Taiwan
6Department of Psychiatry, Chang Gung Memorial Hospital at Linkou, 5
Fusing Street, Kueishan, Taoyuan, Taiwan
Full list of author information is available at the end of the article
© 2013 Chien et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orworldwide is approximately 1 to 2.6%, with a male
predominance [2,3]. The etiology of ASD is mainly
attributable to genetic factors. The estimated heritability
of ASD is more than 90%, and the genetic underpinnings
of ASD are heterogeneous and complex, involving mul-
tiple genes, gene-gene interactions, and gene-environmental
interactions [4,5]. Identification of genetic underpinnings
can shed light on the pathogenesis of ASD, and facilitate
the development of new treatments for ASD. The genetic
risk factors for ASD identified so far range from common
variants conferring a small clinical effect to rare mutations
that confer a high clinical effect [6]. The high heterogeneity
of ASD may account for the varied clinical presentations
of patients with ASD. Several genes have been found
to be associated with ASD, but more genes remain to
be discovered.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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technology allowing simultaneous measurement of hun-
dreds to thousands of gene transcripts, and is useful for
large-scale gene discovery [7]. This technology has been
used in several post-mortem brain studies of psychiatric
disorders, including schizophrenia, bipolar disorder, and
autism [8-11]. Since there are several limitations to the
use of the post-mortem brain tissue in gene expression
studies, and the study of fresh brain tissue from living
psychiatric patients is impractical at the present time,
several studies have reported the use of peripheral blood
cells and lymphoblastoid cell lines (LCL) as surrogates
for brain tissue in the gene expression studies of mental
disorders [12-16]. In addition, a moderate correlation of
gene expression between peripheral blood cells and
brain tissue in humans has been reported, supporting
the usefulness of peripheral blood cells in the gene
expression studies for psychiatric research [17].
Comparative gene expression profiling analysis of LCL
has been conducted in several autism studies [18-22]. For
example, several differentially expressed genes important
to the development, structure, and/or function of the
nervous system were detected in monozygotic twins
discordant for autism using this method [18]. Another
genome-wide expression profiling of LCL identified shared
pathways among different forms of autism [19]. Also,
altered pathways in neural development and steroid
biogenesis were detected in a study of total gene expression
profiling analysis of LCL in autistic patients and their
unaffected sib-pairs [20]. Another study found that the
imbalance of cellular and mitochondrial glutathione
redox in LCL was associated with autism [21]. LCL was
also used successfully to investigate the role of microRNA
in autism [22]. Taken together, these studies support the
usefulness of comparative gene expression profiling analysis
of LCL in the molecular genetic study of autism [23].
The above-mentioned findings attracted our interest in
identifying novel differentially expressed genes associated
with autism in our population using comparative gene
expression profiling analysis of LCL. We first conducted a
comparative gene expression profiling analysis of LCL in a
sample of 16 male patients with ASD and 16 male control
subjects as an initial screening of differentially expressed
genes associated with autism. In the second stage, we
verified the authenticity of a selected differentially expressed
gene, FOXP1, in an expanded sample of 83 male patients




The study was conducted in two tiers. In the first experi-
ment, microarray-based total gene expression profiling
analysis was performed with 20 male patients with ASDand 20 male control subjects, but only 16 of each group
passed the quality control of the experiment and they were
subjected to further analysis. In the second experiment,
the transcript level of FOXP1 was compared between 83
male patients with ASD and 83 healthy male controls. The
sample included the 20 male patients and 20 male control
subjects from the first tier of the experiment. All the
patients were recruited from the outpatient clinics of
psychiatric departments in two medical centers (National
Taiwan University Hospital [NTUH] in Taipei and
Chang-Gung Memorial Hospital (CGMH in Kueishan).
All subjects were Han Chinese. The clinical diagnoses
of probands were made by senior board-certified child
psychiatrists according to the DSM-IV diagnostic criteria
for autistic disorder or Asperger’s disorder, and were further
confirmed by structural interviews using the Chinese
version of the Autism Diagnostic Interview-Revised (ADI-R)
[24-27]. The ADI-R [24] is a standardized, comprehensive,
semi-structured, investigator-based interview scale that
was designed for interviewing the caregivers/parents to
obtain information on the developmental and behavioral
aspects of ASD of children with a mental age from about
18 months to adulthood. The behavioral aspects of ASD
assessed by the ADI-R include reciprocal social interactions,
communication, and repetitive stereotyped behaviors/
interests. Gau and colleagues have prepared the Chinese
version of the ADI-R, which was approved by the World
Psychological Association (WPS) in May 2007, for use in
this study [25-27].
The case group in the first tier of the experiment
consisted of 20 male probands, aged 9.1 ± 3.2 years
(range 4 to 18 years old). These participants were selected
from a family cohort of 393 probands with ASD (373
with autistic disorder and 20 with Asperger’s disorder)
[27] because they had the highest severity scores for
problems in verbal communication and social reciprocity
based on the ADI-R interview and clinical assessments.
Probands in the original cohort with fragile X syndrome
or Rett’s disorder, and probands who had a previously
identified chromosomal abnormality associated with autism,
or had any other neurological or medical conditions,
were excluded from the study. The control group
consisted of 20 males (mean age: 37.15 ± 16.90 years;
range 18 to 67 years) who were recruited among the
cohort of individuals receiving regular medical checkups
in a local medical center.
In the second tier of the experiment, a total of 83 male
patients with ASD (including 20 from the first tier of the
experiment), aged 10.2 ± 4.6 years (range 3 to 23 years),
were recruited. The control group consisted of 83 males
(including 20 from the first tier of the experiment), aged
43.5 ± 12.7 years (range 18 to 63 years) who were
recruited from among individuals who received regular
medical checkups in a local medical center. The mental
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subject were evaluated by a senior psychiatrist using the
Mini International Neuropsychiatric Interview (MINI);
subjects diagnosed with a DSM-IV axis 1 disorder including
ASD were excluded. The Research Ethics Committee
of the two research sites approved this study (IRB ID:
9561709027 for NTUH and C20060905 for CGMH).
Written informed consent and child assent were obtained
from the parents and the probands, respectively, after the
purposes and procedures of the study were fully explained
and confidentiality was ensured.
Preparation of lymphoblastoid cell line, total RNA and cDNA
Immortalized LCL from each subject was established by
transforming lymphocytes with Epstein-Barr virus (EBV)
following the procedures described elsewhere [16]. Total
RNA from the LCL was extracted using TRIZOL Total
RNA Isolation Reagent according to the manufacturer’s
instructions (Invitrogen Life Technologies, Carlsbad,
California, USA). The cDNA was prepared using Super-
script II RNase H- Reverse Transcriptase (Invitrogen Life
Technologies). The details were described in our previous
report [16].
Microarray-based total gene expression experiment
The microarray experiment was performed at the Core
Laboratory of National Taiwan University Hospital, Taipei
Taiwan using the Affymetrix Human Genome U133 Plus
2.0 Array (Affymetrix Inc., Santa Clara, CA, USA). The
experimental procedures followed the protocols provided
by the manufacturer.
Identification of differentially expressed genes
The intensity files of all the subjects were input into the
computer program GAP: Generalized Association Plots
[28,29] (http://gap.stat.sinica.edu.tw/Software/GAP/index.
htm) for quality control using visualization and descriptive
statistics. The chips that passed the quality control were
subjected to further differentially expressed gene analysis.
The data of the chips were normalized using the Robust
Multi-array Analysis (RMA) method [30]. In order to filter
out probe sets with low variations and to reduce the
impact of multiple comparisons, we kept only the 1,000
probe sets with the largest standard deviations. A differ-
entially expressed probe set was defined as a P value
smaller than 0.05 for a Student’s t-test adjusted by the
false discovery rate [31] of 5% and fold-change greater
than 2.
Pathway analysis
We performed gene set enrichment analysis (GSEA) on
the entire expression profile for all 32 gene chips using
the GSEA software (v2.0.10) (http://www.broadinstitute.
org/gsea/index.jsp) [32,33]. The phenotype of subjectcategory (ASD and Control) was employed as phenotype
annotation for GSEA.
In addition to GSEA, we also carried out pathway analysis
using DAVID (Database for Annotation, Visualization and
Integrated Discovery) [34] and verified the results from
GSEA (v2.0.10) and DAVID (v6.7) with hypergeometric test
using the runHyperKEGG procedure in EMA v1.3.1 (A R
package for Easy Microarray data Analysis) [35]. Analysis
with all three environments (GSEA, DAVID, and EMA)
was based on the gene population of Affymetrix Human
Genome U133 Plus 2.0 Array annotation data (chip
hgu133plus2) with KEGG v3.1 gene symbol as the gene set
and pathway database. The lists of up- and downregulated
gene probe sets were fed to DAVID and runHyperKEGG.
Real-time quantitative PCR
RT-qPCR was performed using the SYBR Green method
and implemented in the StepOnePlus Real-Time PCR
System according to the manufacturer’s protocol (Applied
Biosystems, Forster City, CA, USA). The detailed proce-
dures were described in our previous report [16]. The
relative standard curve method was used for quantifica-
tion of mRNA expression (User Bulletin #2 ABI PRISM
7700 sequence detection system). With this method, serial
dilutions of known amounts of RNA from a reference
sample (pooled from 40 LCLs of male controls) were used
to generate an external standard curve. For each unknown
sample the relative amount was calculated using linear
regression analysis from their respective standard curves.
The expression level of FOXP1 mRNA was normalized by
18S rRNA. The18S rRNA reference gene was measured
using pre-developed TaqMan assay reagents 18S rRNA
MGB according to the manufacturer’s protocol (Applied
Biosystems). All experiments were performed in duplicate.
Primer sequences for PCR amplification were designed
using online Primer3 software (http://bioinfo.ut.ee/pri
mer3/). All the sequences of primer sets used for RT-
qPCR are listed in Table 1.
Results
Characteristics of patients with Autism Spectrum
Disorders
The ADI-R interviews regarding the past behaviors revealed
that the 16 patients, who underwent the microarray
experiment, scored 24.31 ± 3.88 (range, 14 to 28) in
the ‘qualitative abnormalities in reciprocal social interaction’
(cut-off = 10), 17.69 ± 2.98 (range, 14 to 28) in the ‘qualita-
tive abnormalities in communication, verbal’ (cut-off = 8),
8.94 ± 2.72 (range, 4 to 14) in the ‘qualitative abnormalities
in communication, nonverbal’ (cut-off = 7), and 8.69 ± 2.24
(range, 5 to 12) in the ‘restricted, repetitive and stereotyped
patterns of behaviors’ (cutoff = 3). The average age at
which the 16 patients said their first word was 27.5 ± 9.9
(range, 12 to 42) months and at which they said their first
Table 1 Sequences of primers used in the real-time quantitative PCR experiments in this study
Gene Forward primer Backward primer Ta
FOXP1 5′-CAGATATTGCGCAGAACCAA-3′ 5′-GCAAACATTCGTGTGAACCA-3′ 60
FOXP2 5′-AGCAAATGCAGCAGATCCTT-3′ 5′-TGCTGCAAAAGCTGAAGATG-3′ 60
CNTNAP2 5′-CAGCTCCTCCTCCATCTCTG-3′ 5′-TCACCCAATCTGAGCTGCTA-3′ 60
Ta, annealing temperature. FOXP1[GenBank:NM_001012505.1], FOXP2[GenBank:NM_148898.3], CNTNAP2[GenBank:NM_014141.5].
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current average intelligence quotients (IQ) were 82.13 ±
16.23 (range 62 to 117) for full-scale IQ, 89.13 ± 14.63
(range, 68 to 113) for performance IQ, and 78.44 ± 20.34
(range, 45 to 118) for verbal IQ assessed by the Wechsler
Intelligence Scale for Children-3rd edition.
The ADI-R results from the parents of 83 patients
showed that the 83 patients scored 24.07 ± 4.78 in the
‘qualitative abnormalities in reciprocal social interaction’
(cut-off = 10), 18.05 ± 3.74 in the ‘qualitative abnormalities
in communication, verbal’ (cut-off = 8), 10.14 ± 2.41in the
‘qualitative abnormalities in communication, nonverbal’
(cut-off = 7), and 7.76 ± 2.41 in the ‘restricted, repetitive
and stereotyped patterns of behaviors’ (cutoff = 3). The
average age at which first word was said was 33.3 ± 16.6
(range, 12 to 84) months and that they had their first
phrase was said was 49.9 ± 23.1 (range, 15 to 138) months.
The average full-scale IQ, performance IQ, and verbal IQ
of these 83 patients were 89.31 ± 21.52 (range, 62 to 130),
93.74 ± 19.61 (range, 68 to 140), and 86.89 ± 24.49 (range,
46 to 125), respectively, as assessed by the Wechsler
Intelligence Scale for Children-3rd edition. All the
probands had abnormal development evident before
30 months of age based on the ADI-R interview and
validated by the medical records.Identification of differentially expressed genes
The microarray data of 16 patients and 16 male controls
passed the quality control. The data of 32 gene chips
were then normalized using the RMA method [30].
The descriptive statistics for the distribution of standard
deviations of all 54,675 probe sets were in the ranged from
0.025 to 3.668 with the 25th percentile as 0.157, median
as 0.202, the 75th percentile as 0.298, and mean as 0.260;
and the 98.17th (1,000 among 54,675) percentile was
0.835. Two hundred and fifty-two probe sets of 1,000
probe sets had standard deviations greater than 0.835
expressed differentially among the two groups with a P
value less than 0.05 for a Student’s t-test adjusted by the
false discovery rate [31] of 5% and fold-change greater
than 2. These 252 differentially expressed probe sets
corresponded to 202 genes with 89 of them as upregulated
and 113 as downregulated transcripts in the ASD group
compared to the control group. The list of differentially
expressed genes is shown in Additional file 1.Pathway analysis
We performed gene set enrichment analysis on the entire
expression profile of all 32 gene chips using the GSEA
software (v2.0.10). The most significant 20 KEGG signal-
ing pathways for both up- and downregulated gene sets in
the significance order (size of P values) of GSEA are listed
in the Additional file 2. The results of pathway analysis
of DAVID and runHyperKEGG are also shown in the
Additional file 2. Seven pathways were commonly found
in three analyses, including the long-term depression,
the vascular smooth muscle contraction, the arrhythmo-
genic right ventricular cardiomyopathy (ARVC), the gly-
cerophospholipid metabolism, the allograft rejection, the
Jak-STAT signaling pathway, the toll-like receptor signaling
pathway, and the RIG-I-like receptor signaling pathways.
Verification by real-time quantitative PCR
The authenticity of the differential expression of FOXP1
was first verified between the 20 ASD and 20 control
subjects using RT-qPCR. The average expression level of
FOXP1 in the 20 patients with ASD (4.57 ± 3.04) was
significantly higher than that of the control subjects
(1.89 ± 2.64, P = 0.005). The upregulation of FOXP1
gene expression was further supported by an expanded
sample size of 83 male ASD patients and 83 male control
subjects. This expanded sample size included the initial 20
patients and 20 control subjects. The average transcript
level of FOXP1 in the patient group (10.46 ± 11.34)
was significantly higher than that in the control group
(5.17 ± 4.20, P = 0.001). The distribution and mean of
the FOXP1 transcript level of LCL in 83 patients and 83
controls are shown in Figure 1.
Discussion
Aberrant language development is one of the clinical
characteristics of autism. Mutations of FOXP2 have been
linked to speech and language disorders and ASD [36-38].
FOXP1 is a member of subfamily P of the forkhead box
(FOX) transcription factor family and forms a heterodimer
with FOXP2 [39,40]. The elevated mRNA level of FOXP1
in patients with ASD in the initial expression microarray
experiment attracted our attention; hence, it was selected
for further validation in an expanded sample size using
RT-qPCR. The present study showed significant elevation
of the mRNA level of FOXP1 in patients with ASD
compared to that in the control group. Our finding
Figure 1 Scatter plot of the FOXP1 mRNA level as normalized
by 18S rRNA in 83 male patients with Autism Spectrum
Disorders (ASD) and 83 male control subjects. Horizontal line
indicates the mean of FOXP1 transcript.
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involved in the pathogenesis of ASD. However, the inter-
pretation of the result should be cautious as there was a
significant difference in the mean age between the two
groups, which might be a confounder affecting FOXP1
gene expression. We were not able to obtain blood from
the children and young adolescents as the age-matched
controls because of ethical considerations and patient
protection, which is a limitation of this study. In addition,
the findings from LCL can only be considered as indirect
evidence reflecting what may happen in the brain.
The FOXP1 gene encodes a member of the forkhead
box transcription factor family that contains a DNA-
binding domain and a protein-protein interaction domain.
The FOXP1 gene functions as a transcription repressor
[39,41,42], and is widely expressed in the developing and
mature brain. The gene has been suggested to be involved
in the development and function of the brain [41,43]. In
the literature, three subjects with mental retardation and
significant language and speech deficits were detected to
have heterozygous deletions overlapping the FOXP1 gene
[44]. Two mentally retarded individuals with autistic
features were detected to have a de novo intergenic deletion
and a de novo nonsense mutation in the FOXP1 gene,
respectively [45]. In an exome sequencing study of 20
sporadic ASD patients (simplex ASD), a de novo single-
base insertion in FOXP1 that introduces a frameshift and a
premature stop codon was identified in a severely affectedpatient [46]. These data suggest that haploinsufficiency or
hypomorphic mutations of FOXP1 with reduced expres-
sion or deficient activity of FOXP1 are associated with
syndromic or non-syndromic ASD. However, these
FOXP1 mutations associated with ASD are rare; they may
not apply to the pathogenesis of autism in general. In the
present study, we found that increased FOXP1 gene
expression was associated with autism in general. Our
finding may expand our understanding about the relation-
ship of FOXP1 with autism.
FOXP1 protein was known to interact with another
subfamily member FOXP2 to form a heterodimer and co-
expressed with FOXP2 in several brain regions, suggesting
close functional collaboration between the two proteins
[39,40]. Contactin-associated protein-like 2 (CNTNAP2),
a neurexin family protein that functions as a neuronal
adhesion molecule and receptor, was found to be a direct
neural target bound by human FOXP2 protein [47]. Muta-
tions of FOXP2 and CNTNAP2 were linked to speech and
language disorders and ASD [36-38,48-51]. Taken together,
these data indicate that interactions among FOXP1, FOXP2,
and CNTNAP2 genes may play an essential role underlying
the pathogenesis of syndromic and non-syndromic ASD.
In a more recent study, forkhead box protein p1 was
found to function as a transcriptional repressor of immune
signaling in the mouse brain, and was involved in the
pathophysiology of Huntington’s disease [52]. The study
suggested that Foxp1-regulated pathways might be im-
portant mediators of neuronal-glial cell communication.
Thus, the increased FOXP1 gene expression in the LCL of
ASD patients as found in this study may offer a new
insight that dysregulated immune signaling in the brain
contributes to the pathogenesis of ASD.
A previous study demonstrated that FOXP2 protein
directly binds to intron 1 of the CNTNAP2 gene and
significantly downregulates the mRNA levels of CNTNAP2
[47]. This interaction was further supported by the findings
in a study of Foxp2 R553H knock-in mice [53], which
showed a significant increase in the Cntnap2 mRNA level
in the cerebellum of the transgenic animal [53]. Thus, we
inferred that increased FOXP1 gene expression may lead
to increased expression of the FOXP2 gene through a
feedback mechanism, which may in turn reduce the gene
expression of CNTNAP2 in patients with ASD. We
hypothesized that there might be significant differences in
the gene expression of FOXP2 and CNTNAP2 in LCL
between patients with ASD and control subjects. To
address this issue, we attempted to measure the mRNA
of FOXP2 and CNTNAP2 in LCL in our subjects using
RT-qPCR. However, the mRNA levels of these two genes
were too low to be detected in our system.
The present study may have several implications. First,
as LCL is derived from the EBV transformation of lym-
phocytes of peripheral blood, it would be interesting to
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sion in the peripheral blood cells. If so, the increased
FOXP1 expression can be considered as a potential bio-
marker of ASD in future studies. Second, recent reports
indicate that the expression of FOXP1 is subject to regu-
lation by cis-acting SNPs, methylation, and microRNA
[54-57], and thus, it would be interesting to explore the
underlying mechanisms that may lead to increased ex-
pression of the FOXP1 gene in ASD. Third, recent
studies have demonstrated the feasibility of
establishing induced neuronal cells from induced
pluripotent stem cells (iPSC) [58] or directly from
non-neuronal somatic cells [59]. Hence, it would be
interesting to verify whether the increased expression
of FOXP1 in LCL of ASD patients can be observed in
the induced neuronal cells. Furthermore, it would also
be interesting to measure the expression levels of FOXP2
and CNTNAP2 in the induced neuronal cells that cannot
be detected in LCL and investigate their interactions
with FOXP1.
In a recent review of studies of genome-wide expression
analysis in LCL or blood cells in ASD patients, Voineagu
reported that not much of a convergent pathway was
found in terms of dysregulated pathways from several
studies he reviewed [60]. He provided several explanations
for such discrepant findings, including differences in study
designs, sample sizes, and the clinical heterogeneity of
patients with ASD [60]. Nevertheless, given no overlap of
specific pathways and genes among different gene expres-
sion studies of peripheral tissues in autism patients, he
reported that an upregulation of several genes involved in
immune response is common to several studies, which is
compatible with the findings from several total gene
expression studies of brain tissue in autism patients [60].
In the present study, when we carried out pathway analysis
using three platforms, we found several immune-related
pathways showing significant differences between the ASD
patients and controls, including the RIG-I-like receptor
signaling, the toll-like receptor signaling, the allograft
rejection, the primary immunodeficiency, the cytokine-
cytokine receptor interaction, the chemokine signaling,
the intestinal immune network for IgA production,
and the Jak-STAT signaling pathways. Our findings are
compatible with several previous studies and support
the notion that dysregulated immunological pathways
may be involved in the pathogenesis of ASD [60]. In
addition, we found several other pathways showing signifi-
cant differences between the ASD patients and controls in
three platforms, such as the long-term depression, the vas-
cular smooth muscle contraction, the arrhythmogenic right
ventricular cardiomyopathy, and the glycerophospholipid
metabolism pathways. The detection of the long-term
depression pathway is consistent with the finding from
the study by Kong and colleagues [61]. Taken together,our findings in pathway analysis support the idea that
autism is a complex genetic disorder.
Conclusions
Our study suggests that comparative gene expression
profiling analysis of LCL is a useful tool to discover
novel genes associated with autism. In this study, we
found a significant elevation of the gene transcript of
FOXP1 in patients with ASD, suggesting that increased
FOXP1 gene expression might be involved in the patho-
genesis of ASD. Nevertheless, limitations of this study,
such as the small sample size, a significant difference
in the mean age between the two groups, and the
non-brain tissue of the study, should be taken into
consideration while assessing these findings.
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